Immatics (IMTX) Net Equity Issued and Repurchased (2020 - 2025)
Immatics (IMTX) posted Net Equity Issued and Repurchased of $124.9 million for Q4 2025, up 2670825.82% sequentially from $4676.2 in Q3 2025, and down 30.62% YoY from $180.0 million in Q4 2024.
Immatics (IMTX) Net Equity Issued and Repurchased (2020 - 2025) Analysis & Trends
Immatics has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $124.9 million in Q4 2025.
- Quarterly Net Equity Issued and Repurchased fell 30.62% year-over-year to $124.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $305.0 million (down 17.51% YoY) and the FY2025 annual result came in at $121.2 million, down 67.34% from the prior year.
- Net Equity Issued and Repurchased improved to $124.9 million in Q4 2025 per IMTX's latest filing, from $4676.2 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $201.7 million in Q1 2024 and troughed at -$97.2 million in Q4 2023.
- A 5-year average of $52.1 million and a median of $3.9 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2022 and 2023: Net Equity Issued and Repurchased surged 532544.04% in 2022, then sank 183.93% in 2023.
- Over 5 years, Net Equity Issued and Repurchased stood at $21735.4 in 2021, then soared by 532544.04% to $115.8 million in 2022, then tumbled by 183.93% to -$97.2 million in 2023, then surged by 285.25% to $180.0 million in 2024, then tumbled by 30.62% to $124.9 million in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $124.9 million, $4676.2, and $180.0 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immatics | 1.27 Bn | 719.31 Mn | - | 124.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 124.90 Mn |
| Dec 31, 2025 | 124.90 Mn |
| Sep 30, 2025 | 4,676.22 |
| Sep 30, 2025 | 4,676.22 |
| Dec 31, 2024 | 180.01 Mn |
| Dec 31, 2024 | 180.01 Mn |
| Sep 30, 2024 | 85,661.12 |
| Sep 30, 2024 | 85,661.12 |
| Jun 30, 2024 | -12.05 Mn |
| Jun 30, 2024 | -12.05 Mn |
| Mar 31, 2024 | 201.70 Mn |
| Mar 31, 2024 | 201.70 Mn |
| Dec 31, 2023 | -97.17 Mn |
| Dec 31, 2023 | -97.17 Mn |
| Sep 30, 2023 | 56.38 Mn |
| Sep 30, 2023 | 56.38 Mn |
| Dec 31, 2022 | 115.77 Mn |
| Dec 31, 2022 | 115.77 Mn |
| Sep 30, 2022 | 3.93 Mn |
| Sep 30, 2022 | 3.93 Mn |